-
公开(公告)号:US20200247747A1
公开(公告)日:2020-08-06
申请号:US16777273
申请日:2020-01-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Yasushi Hattori , Yuhei Miyanohana , Yuichi Kajita , Tatsuki Koike , Yasutaka Hoashi , Norihito Tokunaga , Alexander Martin Pawliczek , Tsuneo Oda , Tohru Miyazaki , Yoshiteru Ito , Kohei Takeuchi , Keisuke Imamura , Takahiro Sugimoto
IPC: C07D207/14 , C07D417/06 , C07D407/08
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
公开(公告)号:US10428023B2
公开(公告)日:2019-10-01
申请号:US16052967
申请日:2018-08-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike , Kohei Takeuchi , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tohru Miyazaki , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
IPC: C07D211/56 , A61P25/00 , C07D205/04 , C07D207/14 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/06 , C07D405/10 , C07D405/12 , C07D413/06 , C07D417/06 , C07D417/14 , C07D405/06 , C07D211/36
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
公开(公告)号:US11059780B2
公开(公告)日:2021-07-13
申请号:US16491811
申请日:2018-03-07
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masaki Daini , Yuhei Miyanohana , Satoshi Mikami , Yuichi Kajita , Masaki Ogino , Tatsuki Koike , Kohei Takeuchi
IPC: C07D207/12 , C07D405/12 , C07D403/12 , C07D405/14 , C07D401/14 , C07D417/14 , C07D403/14 , C07D493/08 , C07D487/10 , C07D498/10 , C07D471/04 , C07D413/12 , C07D491/107 , C07D487/08
Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US12077522B2
公开(公告)日:2024-09-03
申请号:US17256330
申请日:2019-06-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Tatsuhiko Fujimoto , Koichiro Fukuda , Hiromichi Sugimoto , Kentaro Rikimaru , Yoshihiro Banno , Takahiro Matsumoto , Norihito Tokunaga , Yoshihide Tomata , Yuji Ishichi , Shogo Marui , Tsuneo Oda , Tohru Miyazaki , Yasutaka Hoashi , Yasushi Hattori , Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike
IPC: C07D401/14 , C07D211/56 , C07D405/14
CPC classification number: C07D401/14 , C07D211/56 , C07D405/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US11028048B2
公开(公告)日:2021-06-08
申请号:US16777273
申请日:2020-01-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Yasushi Hattori , Yuhei Miyanohana , Yuichi Kajita , Tatsuki Koike , Yasutaka Hoashi , Norihito Tokunaga , Alexander Martin Pawliczek , Tsuneo Oda , Tohru Miyazaki , Marilena Pira , Javier Miguelez-Ramos
IPC: C07D207/14 , C07D407/08 , C07D417/06
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US10202376B2
公开(公告)日:2019-02-12
申请号:US15538297
申请日:2015-12-21
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Eiji Kimura , Yuhei Miyanohana , Masaki Ogino , Yuta Tanaka , Makoto Fushimi , Tomohiro Okawa , Yuki Hanya , Tatsuki Koike
IPC: C07D471/04 , A61K31/437 , C07D487/04 , A61P25/00 , A61P29/00
Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.
-
公开(公告)号:US11440883B2
公开(公告)日:2022-09-13
申请号:US16811426
申请日:2020-03-06
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike , Kohei Takeuchi , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tohru Miyazaki , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
IPC: C07D211/56 , C07D211/36 , C07D405/06 , A61P25/26 , C07D409/10 , A61P25/00 , C07D205/04 , C07D207/14 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/06 , C07D405/10 , C07D405/12 , C07D413/06 , C07D417/06 , C07D417/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US11319286B2
公开(公告)日:2022-05-03
申请号:US16635408
申请日:2018-08-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Tatsuhiko Fujimoto , Kentaro Rikimaru , Koichiro Fukuda , Hiromichi Sugimoto , Takahiro Matsumoto , Yuichi Kajita , Satoshi Mikami , Yuhei Miyanohana , Tatsuki Koike , Masaki Daini , Masaki Ogino , Kohei Takeuchi , Tohru Miyazaki , Yoshiteru Ito , Norihito Tokunaga , Takahiro Sugimoto , Tsuneo Oda , Yasutaka Hoashi , Yasushi Hattori , Keisuke Imamura
IPC: C07D207/14 , C07D401/14 , C07D403/06 , A61P25/28
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US11034700B2
公开(公告)日:2021-06-15
申请号:US16491794
申请日:2018-03-07
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Satoshi Mikami , Masaki Daini , Yuhei Miyanohana , Hideo Suzuki , Kenichiro Shimokawa , Yuichi Kajita , Masaki Ogino , Tatsuki Koike , Kohei Takeuchi
IPC: A61K31/40 , C07D491/107 , C07D207/12 , C07D207/14 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/10 , C07D409/06 , C07D409/12 , C07D413/10 , C07D413/12
Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号:US12091410B2
公开(公告)日:2024-09-17
申请号:US17413473
申请日:2019-12-11
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Yuichi Kajita , Yuhei Miyanohana , Tatsuki Koike , Yasutaka Hoashi , Yasushi Hattori , Norihito Tokunaga , Tsuneo Oda , Tohru Miyazaki , Dilhumar Uyghur , Yoshiteru Ito , Kohei Takeuchi , Keisuke Imamura , Takahiro Sugimoto , Koichiro Fukuda , Yasuhisa Kohara , Rei Okamoto , Taiichi Ohra , Naoki Miyamoto , Yoshito Terao , Masanori Kawasaki
IPC: C07D471/04 , C07D215/38 , C07D231/56 , C07D277/64 , C07D401/14
CPC classification number: C07D471/04 , C07D215/38 , C07D231/56 , C07D277/64 , C07D401/14
Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
-
-
-
-
-
-
-
-